Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fuji
Novartis
Cerilliant
Federal Trade Commission
QuintilesIMS
Cantor Fitzgerald
Argus Health
Mallinckrodt
Boehringer Ingelheim

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,664,231

« Back to Dashboard

Which drugs does patent 8,664,231 protect, and when does it expire?

Patent 8,664,231 protects RASUVO and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.
Summary for Patent: 8,664,231
Title:Concentrated methotrexate solutions
Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.
Inventor(s): Will; Heiner (Hamburg, DE)
Assignee: Medac Gesellschaft fuer Klinische Spezialpraepararate mbH (Wedel, DE)
Application Number:12/374,528
Patent Claim Types:
see list of patent claims
Use; Formulation; Device; Dosage form;

Drugs Protected by US Patent 8,664,231

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-001 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-002 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-003 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-004 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-005 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-006 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-007 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-008 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-009 Jul 10, 2014 DISCN No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Medac Pharma Inc RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776-010 Jul 10, 2014 RX No No ➤ Subscribe ➤ Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,664,231

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2006 033 837Jul 21, 2006
PCT Information
PCT FiledJuly 20, 2007PCT Application Number:PCT/EP2007/006491
PCT Publication Date:January 24, 2008PCT Publication Number: WO2008/009476

International Patents Family Members for US Patent 8,664,231

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 101260554 ➤ Subscribe
South Korea 20090079876 ➤ Subscribe
Japan 5683810 ➤ Subscribe
Japan 2009544636 ➤ Subscribe
Croatia P20110148 ➤ Subscribe
Spain 2355399 ➤ Subscribe
European Patent Office 2292235 ➤ Subscribe
European Patent Office 2046332 ➤ Subscribe
Denmark 2046332 ➤ Subscribe
Germany 502007005972 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
US Army
Moodys
US Department of Justice
Deloitte
UBS
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot